Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients

Budi Wiweko, Mila Maidarti, M. Dwi Priangga, Nadia Shafira, Darrell Fernando, Kanadi Sumapraja, Muharam Natadisastra, Andon Hestiantoro

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)


Purpose: To determine whether the measurement of serum AMH can be used to diagnose PCOS and as a tool to predict the prognosis of PCOS.

Methods: This is a case–control study. Women of reproductive age (18–35 years) were recruited consecutively at a tertiary academic hospital during the period of March 2009–October 2011 and were divided into case (PCOS patients defined by the Rotterdam criteria) and control groups (non-PCOS patients). Menstrual history, clinical manifestations of hyperandrogenism, ovarian ultrasound assessments, and the levels of AMH, LH, FSH, and estradiol were collected.

Results: Seventy-one cases and 71 controls were recruited. AMH serum levels were significantly higher in PCOS patients than in controls. The Area Under the Curve (AUC) of the serum AMH assay in PCOS patients reached a value of 0.870. With a cut-off value of 4.45 ng/ml, the serum AMH level had a sensitivity of 76.1 % and a specificity of 74.6 %. The most common phenotypes of PCOS in this study were anovulation and polycystic ovary (63.4 %). However, the mean level of AMH was highest in the phenotypes of anovulation, polycystic ovaries and hyperandrogenism (11.1 ng/ml).

Conclusions: In Indonesian women, AMH can be used as an alternative diagnostic criteria for PCOS patients with a cut-off value of 4.45 ng/ml. AMH value rise when hyperandrogenism is present therefore serum AMH levels also reflect the phenotype of PCOS. However, these findings must be confirmed with larger clinical studies.

Original languageEnglish
Pages (from-to)1311-1316
Number of pages6
JournalJournal of Assisted Reproduction and Genetics
Issue number10
Publication statusPublished - 23 Sept 2014


  • AMH
  • Diagnosis of PCOS
  • PCOS
  • Prognosis of PCOS


Dive into the research topics of 'Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients'. Together they form a unique fingerprint.

Cite this